Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

BDSX - Biodesix, Inc. So'nggi Yangiliklar | Finranks

Home

BDSX

B

Biodesix, Inc. (BDSX)

NGM – Real vaqt narxi. Valyuta: USD

14.21

-0.39 (-2.67%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

14.55

+0.34 (2.42%)

Bozordan keyin: Mar 27, 2026, 7:38 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations

Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo.

Biodesix Announces Third Quarter 2025 Results and Highlights

Biodesix Announces Third Quarter 2025 Results and Highlights

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.